Disease · EFO_0009846

muscle cramp

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. muscle cramp. Diseases, record EFO_0009846. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009846

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: muscle cramp; Open Targets
Open Targets ID: EFO_0009846; Open Targets
Other names: Cramp, Cramp(s), Muscle Cramping, Spasm; Open Targets
NCI Thesaurus: C34827; NCI Thesaurus
Highest stage of its drugs: Approval, for 17 of its 34 drugs, from DailyMed and TTD; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Source
ACETAMINOPHEN	CHEMBL112	Small molecule	Approval	DailyMed	8	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	DailyMed	4	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Approval	DailyMed	4	Drugs and targets
DEXBROMPHENIRAMINE MALEATE	CHEMBL1200638	Small molecule	Approval	DailyMed	2	Drugs and targets
QUININE SULFATE	CHEMBL2359966	Small molecule	Approval	DailyMed	2	Drugs and targets
CIMETROPIUM BROMIDE	CHEMBL2105977	Small molecule	Approval	TTD	1	Drugs and targets
DOXACURIUM	CHEMBL1237123	Small molecule	Approval	TTD	1	Drugs and targets
EPINEPHRINE	CHEMBL679	Small molecule	Approval	DailyMed	1	Drugs and targets
HEXAFLUORENIUM BROMIDE	CHEMBL1200933	Small molecule	Approval	TTD	1	Drugs and targets
MENTHOL	CHEMBL256087	Small molecule	Approval	DailyMed	1	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets78

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRNA1	Muscle-type nicotinic acetylcholine receptor	4	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1134	Drugs and targets
CHRNB1	Muscle-type nicotinic acetylcholine receptor	4	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1140	Drugs and targets
CHRND	Muscle-type nicotinic acetylcholine receptor	4	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1144	Drugs and targets
CHRNE	Muscle-type nicotinic acetylcholine receptor	4	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1145	Drugs and targets
CHRNG	Muscle-type nicotinic acetylcholine receptor	4	Muscle-type nicotinic acetylcholine receptor agonist; Muscle-type nicotinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1146	Drugs and targets
PTGS1	Cyclooxygenase	4	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	4	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	3	Voltage-gated N-type calcium channel alpha-1B subunit blocker; Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA2A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets

1 to 10 of 78

See all 78 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02298868	Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study	Phase 2	10	2015-02-05	Muscle Cramps, Cirrhosis	BACLOFEN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02561702	Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease	Phase 2	4	2018-03-26	Charcot Marie Tooth Disease	MEXILETINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02642484	Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis	Phase 3	200		Liver Cirrhosis	GABAPENTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02642861	Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis	Phase 3	200		Liver Cirrhosis	CYCLOBENZAPRINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02642874	Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients	Phase 3	200		Liver Cirrhosis	METHOCARBAMOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02221570	Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis	Not applicable	100		Muscle Cramps, Liver Cirrhosis	BACLOFEN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02423395	Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis	Phase 3	100		Liver Cirrhosis, Muscle Cramps	ORPHENADRINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05817799	Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease	Phase 2/3	83		Hemodialysis Complication	CARNITINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01271660	A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis	Phase 3	60		Muscle Cramp, Liver Cirrhosis	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT03238898	Botulinum Toxin for Cramps in Diabetic Neuropathy	Phase 2	50		Muscle Cramps Aggravated, Diabetes Mellitus	BOTULINUM TOXIN TYPE A	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Mexiletine vs Placebo: Number of Participants With a Decrease in Cramp Intensity	1 of 4	2 of 4	8	NCT02561702	Trial comparisons
Mexiletine vs Placebo: Number of Participants With a Decrease in Cramp Duration	2 of 4	0 of 4	8	NCT02561702	Trial comparisons
Mexiletine vs Placebo: deaths from any cause	0 of 4	0 of 4	8	NCT02561702	Trial comparisons
Mexiletine vs Placebo: serious adverse events	0 of 4	0 of 4	8	NCT02561702	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34740538	RESULT	1	PubMed
33713287	RESULT	1	PubMed
33139659	RESULT	1	PubMed
30353121	RESULT	1	PubMed
24525835	RESULT	1	PubMed
9029067	RESULT	1	PubMed
8501266	RESULT	1	PubMed
39763581	DERIVED	1	PubMed
35191232	DERIVED	1	PubMed
32956536	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009846

GET https://conductscience.org/api/diseases/v1/EFO_0009846/drugs?page=2

API reference For AI assistants